Multivariate analysis of the ten late-type probe sets in the Mainz cohort.

<p>Multivariate analysis of the ten late-type probe sets in the Mainz cohort.</p

DataSheet_1_Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis.docx

IntroductionVulvar cancer carries a favourable prognosis in early stages. However, therapeutic options for advanced or recurrent cases are limited despite a variety of therapeutic modalities, such as extensive surgical resection, chemotherapy, and radiotherapy. The most important emerging treatment modalities are immune checkpoint inhibitors. This systematic review and meta-analysis aims to assess the efficacy and safety of pembrolizumab, an immune checkpoint inhibitor, in women with advanced vulvar cancer.Materials and methodsFollowing a comprehensive search, review, and appraisal, two relevant single-arm studies were included. Meta-analysis was conducted using R4.3.0 software and RStudio 2023.03.0, presenting the overall effect size with a 95% confidence interval. Heterogeneity was assessed using I2 and the Cochrane Q χ2 statistics.ResultsOut of 154 studies screened for eligibility, two single-arm studies involving 119 patients receiving pembrolizumab for advanced vulvar cancer were included. The pooled objective response rate (ORR) was overall 10% (95% CI: 0.00-0.84) and 9% (95% CI: 0.00-0.89) in the PD-L1 positive subgroup. In the intention-to-treat (ITT) population, 31% (95% CI: 0.04-0.85) exhibited any clinical benefit (complete response, partial response, or stable disease). In the ITT population at six months, progression-free survival (PFS) was 19% (95% CI: 0.01-0.82), and overall survival (OS) was 48% (95% CI: 0.08-0.90). At 12 months, PFS decreased to 9% (95% CI: 0.00-0.85), and OS was 33% (95% CI: 0.04-0.85). No statistically significant heterogeneity was observed in PFS and OS analyses.Discussion and conclusionThis study suggests that one-third of women with advanced or recurrent vulvar cancer may, without the influence of PD-L1 status, benefit from pembrolizumab treatment despite a decline in both PFS and OS at 12 months. These findings provide support for considering pembrolizumab in the treatment paradigm for this specific subset of cancer patients.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023391888</p

Identification of early- and late-type genes.

<p>Study design for identification and validation of early-type and late-type genes in node-negative, systemically untreated, ER-positive breast cancer. The number of probe sets identified in each step is given within parentheses.</p

Validated early- and late-type genes.

<p>Kaplan-Meier plots representing validated late-type (A) and early-type (B) genes, for each showing one examples of one gene associated with better prognosis and one gene associated with worse prognosis. The median was used to differentiate between patients with low and high expression. Overlap between early-type and late-type genes with the previously described proliferation metagene (C). Overlap between early-type and late-type genes with genes associated with MFS in a conventional Cox model that considers the entire follow-up period (‘non-time restricted’) (D).</p

Late-type genes that predict metastasis-free survival three years after primary treatment and later.

<p>Late-type genes that predict metastasis-free survival three years after primary treatment and later.</p

Summary of known biological functions for the validated late-type genes.

<p>Summary of known biological functions for the validated late-type genes.</p

Validation of late-type probe sets in tamoxifen-treated cohorts.

<p>Forest plots for the late-type probe sets that were significantly associated with prognosis in the meta-analysis of ER-positive breast cancers treated with adjuvant tamoxifen.</p

Additional file 7: of Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population

Table S5. Univariable Cox regression analysis for distant disease-free survival. (DOCX 16 kb

Additional file 5: of Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population

Table S3. Associations between patient and tumor characteristics and cancer median FOXP3 expression. (DOCX 17 kb

Additional file 1: of Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population

Table S1. Associations between median cancer CXCL13 expression and patient and tumor characteristics in triple-negative patients enrolled in HE10/97. (DOCX 15 kb